MK-0343

Research use only, not for human use.

MK-0343 (MRK-409) is a potent, α2/3 subtype selective, partial GABAA receptor agonist.

MK-0343 (MRK-409) is a potent, α2/3 subtype selective, partial GABAA receptor agonist, shows greater agonist efficacy at the α3 over α1 subtypes; readily penetrates the brain in rats and occupies the benzodiazepine site of GABA(A) receptors with an Occ(50) of 2.2 mg/kg p.o. and a corresponding plasma EC50 of 115 ng/mL; produces anxiolytic-like activity in rodent and primate unconditioned and conditioned models of anxiety.

——

MK0343 readily penetrates the brain in rats and occupies the benzodiazepine site of GABAA receptors, measured using an in vivo [3H]flumazenil binding assay, with an Occ50 of 2.2?mg/kg p.o. and a corresponding plasma EC50 of 115?ng/mL. Animal Model:Male Sprague-Dawley rats (approximately 250–300g) (pharmacokinetics)Dosage:1, 2 or 3?mg/kg Administration:Oral administration Result:Readily penetrated the brain in rats and occupies the benzodiazepine site of GABAA receptors, with an Occ50 of 2.2?mg/kg p.o. and a corresponding plasma EC50 of 115?ng/mL.

MRK-409 | MK0343

Membrane Transporter/Ion Channel

GAT

GAT

Other Indications

——

233275-76-8

397.39

C19H17F2N7O

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (629.12 mM)

CN1N=CN=C1COC2=NN3C(C=C2C4CCC4)=NN=C3C5=C(F)C=CC=C5F

7-Cyclobutyl-3-(2,6-difluorophenyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine

(-20℃)

With Ice Pack

≥ 2 years